Contrave
NDC 50090-2945
View NDC Profile UNII Mappings and RxNorm Concepts.
Product Information
This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
Contrave is a NDA-approved product labeled by A-s Medication Solutions. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a blue product. This product entry covers the primary NDC 50090-2945 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
50090-2945
Proprietary Name:
Contrave Extended-release
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
50090
Product Label ID:
FDA Application Number: [6]
NDA200063
Marketing Category: [8]
NDA - A product marketed under an approved New Drug Application.
Marketing Timeline
Start Marketing Date: [9]
10-22-2014
Listing Expiration Date: [11]
12-31-2022
Exclude Flag: [12]
I
Product Characteristics
Color(s):
BLUE (C48333)
Shape:
ROUND (C48348)
Size(s):
12 MM
Imprint(s):
NB;890 Score:
1
Code Structure Chart
Product Details
What is NDC 50090-2945?
The NDC code 50090-2945 is assigned by the FDA to the product Contrave Extended-release. This pharmaceutical product is labeled by A-s Medication Solutions and is currently categorized as listed product. In terms of distribution, this product is available in a single package configuration. The associated package NDC(s) include: 50090-2945-0. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:30 kg/m2 or greater (obese) or27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).Limitations of Use:The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established.The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NALTREXONE HYDROCHLORIDE (UNII: Z6375YW9SF)
- NALTREXONE (UNII: 5S6W795CQM) (Active Moiety)
- BUPROPION HYDROCHLORIDE (UNII: ZG7E5POY8O)
- BUPROPION (UNII: 01ZG3TPX31) (Active Moiety)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 1551468 - naltrexone HCl 8 MG / buPROPion HCl 90 MG 12HR Extended Release Oral Tablet
- RxCUI: 1551468 - 12 HR bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG Extended Release Oral Tablet
- RxCUI: 1551474 - Contrave 8 MG / 90 MG 12HR Extended Release Oral Tablet
- RxCUI: 1551474 - 12 HR bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG Extended Release Oral Tablet [Contrave]
- RxCUI: 1551474 - Contrave (bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG) 12 HR Extended Release Oral Tablet
* Please review the full disclaimer at the bottom of this page.
Patient Education
Naltrexone and Bupropion
The combination of naltrexone and bupropion is used along with a reduced calorie diet and exercise plan to help adults who are obese, or who are overweight and have weight-related medical problems, to lose weight and then to keep from gaining back that weight. Naltrexone is in a class of medications called opiate antagonists. Bupropion is in a class of medications called antidepressants. These medications work together on two areas of the brain, the hunger center and the reward system, to reduce appetite and help control cravings.
[Learn More]
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".